Waitlist Mortality and Posttransplant Outcomes in African Americans with Autoimmune Liver Diseases

Table 3

Multivariate competing risk regression analysis for death or waitlist removal for clinical deterioration with transplant as a competing risk.

Variables	SHR	95% CI	value
Age	1.03	1.02–1.04	<0.001
Gender (female)	0.71	0.60–0.85	<0.001
Presence of HCC	1.10	0.73–1.65	0.632
Initial MELD	1.05	1.04–1.06	<0.001
No college education	1.04	0.87–1.24	0.661
Payment source
Private	REF
Public	1.56	1.30–1.86	<0.001
Other	1.14	0.41–3.16	0.801
UNOS region
1	REF
2	0.76	0.51–1.14	0.190
3	0.38	0.25–0.58	<0.001
4	0.79	0.51–1.20	0.275
5	0.62	0.41–0.94	0.025
6	0.83	0.49–1.42	0.514
7	0.67	0.44–1.01	0.059
8	0.80	0.52–1.22	0.304
9	0.81	0.52–1.26	0.358
10	0.70	0.47–1.05	0.088
11	0.59	0.39–0.91	0.017
Blood type
A	REF
B	0.66	0.49–0.89	0.007
AB	0.71	0.43–1.17	0.189
O	0.90	0.76–1.08	0.290
African Americans	1.26	1–1.58	0.046

MELD, model for end-stage liver disease. HCC, hepatocellular carcinoma. SHR, subdistribution hazard ratio. CI, confidence interval. REF, reference.